By Fineline Cube PKU Hi-Tech Huatai Pharmaceuticals Co., Ltd. has been blacklisted from China’s national volume-based procurement (VBP) program following serious quality compliance issues identified during regulatory inspections of its amiodarone production line, according to an official notice from the National Drug Alliance Procurement Office.
Regulatory Action Summary
| Item | Detail |
|---|---|
| Company | PKU Hi-Tech Huatai Pharmaceuticals Co., Ltd. |
| Drug Product | Amiodarone |
| VBP Round | Ninth volume-based procurement tender |
| Regulatory Body | Shandong Provincial Medical Products Administration |
| Finding | Serious defects in production line leading to non-compliance |
| Action Date | 09 Jun 2026 |
| Blacklist Period | 09 Jun 2026 – 08 Dec 2027 (18 months) |
| Production Status | Affected production line suspended |
Compliance Violation Details
- Inspection Authority: Shandong Provincial Medical Products Administration
- Product Involved: Amiodarone (antiarrhythmic medication)
- Violation Type: Serious manufacturing defects resulting in non-compliance with Good Manufacturing Practices (GMP)
- VBP Status: Previously won bid in ninth VBP round; now disqualified
- Market Impact: Immediate suspension from supplying amiodarone through national procurement channels
The blacklisting follows a comprehensive inspection that revealed significant deficiencies in the company’s manufacturing processes for amiodarone, a critical cardiovascular medication used to treat and prevent various types of serious irregular heartbeats. The Shandong Provincial Medical Products Administration concluded that these defects posed potential risks to product quality and patient safety.
Market Implications & Competitive Landscape
- VBP Program Context: China’s VBP initiative aims to reduce drug prices by 50-90% through bulk purchasing agreements with qualifying manufacturers
- Financial Impact: Huatai Pharma loses access to substantial government procurement volumes representing approximately 70-80% of China’s public hospital market
- Competitive Opportunity: Rival manufacturers of amiodarone may benefit from reallocation of Huatai’s VBP quota
- Industry Precedent: This marks one of the most significant quality-related disqualifications in recent VBP rounds, signaling stricter enforcement of manufacturing standards
- Reputation Risk: The 18-month exclusion period represents a substantial setback for the company’s institutional business strategy
The National Drug Alliance Procurement Office emphasized that maintaining drug quality remains paramount in China’s healthcare reform efforts, and such enforcement actions demonstrate the government’s commitment to patient safety over cost considerations alone.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory compliance, market access, and competitive dynamics. Actual outcomes may differ due to factors including regulatory appeals, remediation efforts, and evolving policy frameworks.-Fineline Info & Tech